Back
Article
RBC Capital Downgrades Aardvark Therapeutics to Sector Perform, Lowers Price Target to $6
Benzinga Newsdesk  |  Mar 02, 2026 10:38  |  Source: www.benzinga.com
RBC Capital analyst Brian Abrahams downgrades Aardvark Therapeutics (NASDAQ:AARD) from Outperform to Sector Perform and lowers the price target from $18 to $6.
Comments
  • No comments yet. Be the first to comment!

Login to comment